Worldwide Cancer Immunotherapy Industry to 2033 – Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer Immunotherapy Market by Product, Distribution Channel, Application, End Use, and by Region – Global Forecast to 2022-2033” report has been added to ResearchAndMarkets.com’s offering.

The cancer immunotherapy market size is estimated to be USD 110,125.4 million in 2022 and is expected to witness a CAGR of 7.51% during the forecast period 2023-2033.

Companies Mentioned:

• Novartis AG
• Lilly
• Pfizer Inc
• AstraZeneca
• Pfizer Inc
• Merck & Co. Inc
• Bristol-Myers Squibb Company
• Johnson & Johnson Services Inc
• F. Hoffmann-La Roche Ltd
• Genentech Inc (Roche)
• Immunocore Ltd.

Surge in oncology incidence around the world and spike in R&D efforts for the creation of novel oncology treatments are factors contributing to the market growth.

Additionally, rise in funds for the development of innovative therapies and various strategic measures implemented by top companies is supporting the market growth. However, immunotherapy adverse effects are expected to hinder the growth.

Rise in funds for the development of innovative therapies is expected to propel the market growth during the projected period. For instance, the U.S. National Cancer Institute and Cancer Research UK’s Cancer Grand Challenges project provided USD 13 million in funding to a team of Stanford scientists in June 2022. The creation of new immunotherapies, research into extrachromosomal DNA, and analysis of early-stage cancers are all recipients of this funding.

Various strategic measures implemented by top companies is predicted to fuel the market growth during the forecast period. For instance, in August 2022, Genmab A/S and BioNTech SE strengthened their strategic partnership for the creation and introduction of novel immune treatments for the management of various cancer types.

Additionally, Merck & Co., Inc. announced in March 2022 that the US FDA has approved KEYTRUDA. An anti-PD-1 therapy named KEYTRUDA is used to treat advanced endometrial cancer.

Market Segmentation

Product (Revenue, USD Million), 2022 – 2033

• Immunomodulators
• Monoclonal Antibodies
• Oncolytic Viral Therapies & Cancer Vaccines

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

Application (Revenue, USD Million), 2022 – 2033

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Pancreatic Cancer
• Melanoma
• Ovarian Cancer
• Head and Neck Cancer
• Others

End Use (Revenue, USD Million), 2022 – 2033

• Cancer Research Centres
• Hospitals & Clinics
• Others

By Region (Revenue, USD Million), 2022 – 2033

North America

• U.S.
• Canada

Europe

• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East & Africa

• South Africa
• GCC
• Rest of MEA

For more information about this report visit https://www.researchandmarkets.com/r/6ag9at

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900